Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial (Q37783773)

23 August 2017

Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial (English)

1 reference

multicenter clinical trial

23 August 2017

0 references

0 references

Duchenne muscular dystrophy

1 reference

1 reference

Janbernd Kirschner

1

0 references

Rudolf Korinthenberg

object named as

Rudolf Korinthenberg

19

0 references

Maja von der Hagen

15

object named as

Maja von der Hagen

1 reference

23 August 2017

2

Joachim Schessl

1 reference

23 August 2017

18

Gabriele Ihorst

1 reference

23 August 2017

Ulrike Schara

3

1 reference

23 August 2017

Bernd Reitter

4

1 reference

23 August 2017

Georg M Stettner

5

1 reference

23 August 2017

Elke Hobbiebrunken

6

1 reference

23 August 2017

Ekkehard Wilichowski

7

1 reference

23 August 2017

Günther Bernert

8

1 reference

23 August 2017

Simone Weiss

9

1 reference

23 August 2017

Florian Stehling

10

1 reference

23 August 2017

Gert Wiegand

11

1 reference

23 August 2017

Wolfgang Müller-Felber

12

1 reference

23 August 2017

Simone Thiele

13

1 reference

23 August 2017

Ulrike Grieben

14

1 reference

23 August 2017

Jürg Lütschg

16

1 reference

23 August 2017

Claudia Schmoor

17

1 reference

23 August 2017

26 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

9

1 reference

23 August 2017

11

1 reference

23 August 2017

1053-1059

1 reference

Population frequencies of inherited neuromuscular diseases—A world survey

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Glucocorticoid corticosteroids for Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Cyclosporine increases muscular force generation in Duchenne muscular dystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Clinical trial in Duchenne dystrophy. I. The design of the protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Clinical investigation in duchenne dystrophy: 2. Determination of the ?power? of therapeutic trials based on the natural history

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Reference values of maximum isometric muscle force obtained in 270 children aged 4–16 years by hand-held dynamometry

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Long-term benefit from prednisone therapy in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Therapeutic trial of isaxonine in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

A randomized controlled trial of early surgery in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Myoblast transfer in the treatment of Duchenne's muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Prednisone can protect against exercise-induced muscle damage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

Prednisolone-induced changes in dystrophic skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970196-4

7 January 2021

10.1016/S1474-4422(10)70196-4

Identifiers

DOI

1 reference

23 August 2017

1 reference